Ozcan Altan A, Ersoz T Reha, Dulger Erol
Department of Ophthalmology, Cukurova University, Faculty of Medicine, Adana, Turkey.
Cornea. 2007 Oct;26(9):1035-8. doi: 10.1097/ICO.0b013e31812dfab3.
To evaluate the efficacy of topical cyclosporin A 0.05% in the management of severe allergic conjunctivitis.
Seven patients with severe allergic conjunctivitis who were not responding to topical steroids, antihistamines, and mast cell stabilizers were given topical cyclosporin A 0.05%. All patients had an active disease when they were included in the study. Signs and symptoms were recorded before and after treatment.
Seven patients, 6 boys and 1 girl, 6-14 years old, 6 with vernal keratoconjunctivitis and 1 with atopic keratoconjunctivitis, were enrolled in the study. Treatment with topical cyclosporin A 0.05% decreased the severity of symptoms and clinical signs significantly after 6 months (P < 0.05, Wilcoxon signed rank test). In addition, the need for steroids was reduced or even stopped. The patients experienced no side effects during the follow-up periods (mean, 14.0 +/- 2.1 months; range, 8-18 months).
Topical cyclosporin A is an effective treatment in the management of severe allergic conjunctivitis with a benefit as a steroid-sparing agent.
评估0.05%的局部用环孢素A治疗重度过敏性结膜炎的疗效。
选取7例对局部用类固醇、抗组胺药和肥大细胞稳定剂治疗无效的重度过敏性结膜炎患者，给予0.05%的局部用环孢素A治疗。所有患者纳入研究时均患有活动性疾病。记录治疗前后的体征和症状。
7例患者，6例男孩和1例女孩，年龄6至14岁，6例患有春季角结膜炎，1例患有特应性角结膜炎，被纳入研究。0.05%的局部用环孢素A治疗6个月后，症状和临床体征的严重程度显著降低（P < 0.05，Wilcoxon符号秩检验）。此外，类固醇的使用需求减少甚至停用。患者在随访期间（平均14.0 +/- 2.1个月；范围8至18个月）未出现副作用。
局部用环孢素A是治疗重度过敏性结膜炎的有效方法，且具有节省类固醇药物的益处。
